Back to Search Start Over

Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.

Authors :
Rinehardt, Hannah
Kassem, Mahmoud
Morgan, Evan
Palettas, Marilly
Stephens, Julie A.
Suresh, Anupama
Ganju, Akansha
Lustberg, Maryam
Wesolowski, Robert
Sardesai, Sagar
Stover, Daniel
Vandeusen, Jeffrey
Cherian, Mathew
Guillermo Prieto Eibl, Maria del Pilar
Miah, Abdul
Alnahhas, Iyad
Giglio, Pierre
Puduvalli, Vinay K.
Ramaswamy, Bhuvaneswari
Williams, Nicole
Source :
European Journal of Breast Health; Oct2021, Vol. 17 Issue 4, p371-377, 7p
Publication Year :
2021

Abstract

Objective: Leptomeningeal carcinomatosis (LMC), a common complication of advanced malignancies, is associated with high morbidity and mortality, yet diagnosis and treatment decisions remain challenging. This study describes the diagnostic and treatment modalities for LMC and identifies factors associated with overall survival (OS). Materials and Methods: We performed a single-institution retrospective study (registration #: OSU2016C0053) of 153 patients diagnosed with LMC treated at The Ohio State University, Comprehensive Cancer Center, (OSUCCC)-James between January 1, 2010 and December 31, 2015. Results: Median age at diagnosis was 55.7 years, and 61% had Eastern Cooperative Oncology Group baseline performance status =1. Most common primary tumors were breast (43%), lung (26%), and cutaneous melanoma (10%). At presentation, most patients were stage III-IV (71%) with higher grade tumors (grade III: 46%). Metastases to bone (36%), brain (33%), and lung (12%) were the most common sites with a median of 0.5 years (range, 0-14.9 years) between the diagnosis of first metastasis and of LMC. 153 (100%) patients had MRI evidence of LMC. Of the 67 (44%) who underwent lumbar puncture (LP), 33 (22%) had positive cerebrospinal fluid (CSF) cytology. Most patients received radiotherapy for LMC (60%) and chemotherapy (93%) for either the primary disease or LMC. 28 patients received intrathecal chemotherapy, 22 of whom had a primary diagnosis of breast cancer. 98% died with median OS of all patients was 1.9 months (95% CI: 1.3-2.5 months). Conclusion: Despite improved treatments and targeted therapies, outcomes of LMC remain extremely poor. Positive CSF cytology was associated with lower OS in patients who had cytology assessed and specifically in patients with breast cancer. CSF cytology serves as an important indicator for prognosis and helps aid in developing individualized therapeutic strategies for patients with LMC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
25870831
Volume :
17
Issue :
4
Database :
Complementary Index
Journal :
European Journal of Breast Health
Publication Type :
Academic Journal
Accession number :
154551531
Full Text :
https://doi.org/10.4274/ejbh.galenos.2021.2021-4-10